Hennessy Advisors Inc. boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 2.4% during the second quarter, Holdings Channel reports. The fund owned 247,350 shares of the biopharmaceutical company’s stock after buying an additional 5,700 shares during the period. Hennessy Advisors Inc.’s holdings in Pfizer were worth $8,709,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the stock. Bloom Tree Partners LLC purchased a new stake in Pfizer during the first quarter worth about $35,682,000. BlackRock Group LTD boosted its stake in Pfizer by 5.6% in the first quarter. BlackRock Group LTD now owns 59,474,971 shares of the biopharmaceutical company’s stock worth $1,762,838,000 after buying an additional 3,154,116 shares during the last quarter. State of Alaska Department of Revenue boosted its stake in Pfizer by 11.3% in the second quarter. State of Alaska Department of Revenue now owns 371,887 shares of the biopharmaceutical company’s stock worth $13,093,000 after buying an additional 37,647 shares during the last quarter. Charter Trust Co. boosted its stake in Pfizer by 4.3% in the second quarter. Charter Trust Co. now owns 377,918 shares of the biopharmaceutical company’s stock worth $13,306,000 after buying an additional 15,510 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock worth $1,864,446,000 after buying an additional 9,005,107 shares during the last quarter. 69.66% of the stock is owned by hedge funds and other institutional investors.
Pfizer Inc. (NYSE:PFE) traded down 0.305% during midday trading on Wednesday, reaching $33.029. The company had a trading volume of 4,825,363 shares. Pfizer Inc. has a one year low of $28.25 and a one year high of $37.39. The company has a market capitalization of $200.34 billion, a PE ratio of 29.281 and a beta of 0.86. The stock’s 50 day moving average is $34.20 and its 200 day moving average is $34.27.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. The firm earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period last year, the business posted $0.56 earnings per share. Equities research analysts forecast that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 annualized dividend and a yield of 3.62%. Pfizer’s dividend payout ratio (DPR) is presently 95.24%.
PFE has been the subject of a number of analyst reports. Piper Jaffray Cos. set a $54.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, August 23rd. Bank of America Corp. set a $40.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Monday, August 22nd. Jefferies Group reduced their price target on Pfizer from $40.00 to $39.00 and set a “buy” rating for the company in a research report on Tuesday, September 13th. Credit Suisse Group AG reaffirmed an “outperform” rating and issued a $40.00 price target on shares of Pfizer in a research report on Monday, August 22nd. Finally, Argus reaffirmed a “buy” rating and issued a $39.00 price target on shares of Pfizer in a research report on Tuesday, October 4th. Ten research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Pfizer presently has an average rating of “Buy” and a consensus target price of $38.78.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.